MedTrace Logo

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

NCT01648465 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-09-03

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine tumors.

Conditions

  • Gastrointestinal Tumors
  • Pancreatic Tumors
  • Gastrointestinal Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumors

Interventions

DRUG

Everolimus

Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Anna Koumarianou, Dr · 4th Dept of Internal Medicine, University Hospital "Attikon"

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-06
Primary Completion
2017-01-31
Completion
2019-08-06

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648465 on ClinicalTrials.gov